Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|August 7, 2017
IPEC Announces 2017 Award Season Winners
Author(s)Pharmaceutical Technology Editors
The International Pharmaceutical Excipients Council (IPEC) has announced the winners of the 2017 award season.
Advertisement
The International Pharmaceutical Excipients Council (IPEC) Foundation announced the 2017 award season winners, who will be recognized for their contributions to the field of excipients during the IPEC Foundation Awards dinner on Nov. 12, 2017 in San Diego, CA. The recipients of each award are mentioned below.
Dale Eric Wurster, professor at the University of Iowa College of Pharmacy, is the recipient of the Ralph Shangraw Memorial Award. Dr. Stuart C. Porter, director and senior research fellow of Ashland Specialty Ingredients in Wilmington, DE, is the recipient of the Louis Blecher Memorial Outstanding Lifetime Achievement Award. Jie Shen, PhD, assistant professor of the departments of biomedical and pharmaceutical sciences and chemical engineering at the University of Rhode Island, is the winner of the Emerging Researcher Award.
Additionally, Dieter Lubda, PhD, director actives and formulation R&D operations at Merck KGaA-Process Solutions in Darmstadt, Germany, is the winner of the Industry Research Achievement in Excipient Technology Award. Graduate student award winners include Janki Andhariya from the University of Connecticut; Carolina del Pilar Mora Guerrero from Purdue University; Sampada Koranne from the University of Minnesota; Shreya S. Kulkarni from the University of Connecticut; and Tze Ning Hiew from the National University of Singapore.
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
4
PharmTech AI Pulse Check: On-Prem vs. Cloud AI
5